Virpax Pharmaceuticals Inc. is an emerging specialty pharmaceutical company focusing on developing advanced healthcare solutions with its flagship product Probudur, utilizing proprietary liposomal encapsulation for sustained release. The company's collaborative efforts with prestigious institutions like the National Institute of Health/NCATS and U.S. Army Institute of Surgical Research demonstrate its commitment to non-addictive treatments and addressing unmet global needs in various healthcare markets. Virpax is leveraging its drug delivery platforms to target markets such as Post Operative Pain, Severe Pain, Post Cancer Pain, and Rare Pediatric Epilepsy.

Virpax's key milestones include the successful development of Probudur, a liposomal bupivacaine formulation that provides 96 hours of pain control post-injection at the wound site in animal studies. Additionally, the company has made strides in developing Envelta, an intranasal enkephalin powder, and NobrXiol, a cannabidiol intranasal dry powder spray, to address severe pain and rare pediatric epilepsy, respectively. Virpax's partnerships and collaborative agreements highlight its commitment to advancing innovative pharmaceutical solutions for challenging healthcare conditions.

Currently, Virpax Pharmaceuticals is actively involved in the development and testing of its lead product Probudur, Envelta, and NobrXiol, showcasing the efficacy of its drug delivery platforms in providing long-lasting pain relief and managing neurological disorders. These case studies demonstrate Virpax's dedication to addressing unmet medical needs and improving patient outcomes through innovative pharmaceutical solutions.

Virpax Pharmaceuticals has recently reported its 2024 second-quarter results and highlighted recent developments, including positive outcomes from the Probudur swine model pilot study. The company's participation in the Sidoti Virtual Investor Conference and compliance with Nasdaq requirements further indicate its growth and recognition in the pharmaceutical industry. Virpax's positioning in three multi-billion dollar markets and commitment to optimizing patient care globally underscore its strategic vision and impact on healthcare innovation.